PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
411.79%
Revenue growth above 1.5x CVE's 86.57%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
109.76%
Gross profit growth 1.25-1.5x CVE's 98.28%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
390.41%
EBIT growth 50-75% of CVE's 551.00%. Martin Whitman would suspect suboptimal resource allocation.
390.41%
Operating income growth at 50-75% of CVE's 551.00%. Martin Whitman would doubt the firm’s ability to compete efficiently.
134.28%
Net income growth under 50% of CVE's 638.58%. Michael Burry would suspect the firm is falling well behind a key competitor.
135.22%
EPS growth under 50% of CVE's 638.46%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
131.68%
Diluted EPS growth under 50% of CVE's 638.46%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-1.53%
Share reduction while CVE is at 0.03%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.26%
Reduced diluted shares while CVE is at 0.12%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.88%
Maintaining or increasing dividends while CVE cut them. John Neff might see a strong edge in shareholder returns.
-155.54%
Negative OCF growth while CVE is at 6.26%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-428.52%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
485.87%
10Y revenue/share CAGR above 1.5x CVE's 31.48%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
42.39%
5Y revenue/share CAGR 1.25-1.5x CVE's 31.48%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
-15.86%
Negative 3Y CAGR while CVE stands at 31.48%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-873.63%
Negative 10Y OCF/share CAGR while CVE stands at 20.07%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-158.49%
Negative 5Y OCF/share CAGR while CVE is at 20.07%. Joel Greenblatt would question the firm’s operational model or cost structure.
-148.48%
Negative 3Y OCF/share CAGR while CVE stands at 20.07%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
1878.88%
Net income/share CAGR above 1.5x CVE's 1.81% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
4931.70%
5Y net income/share CAGR above 1.5x CVE's 1.81%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
259.43%
3Y net income/share CAGR above 1.5x CVE's 1.81%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
661.15%
Equity/share CAGR of 661.15% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
91.17%
Equity/share CAGR of 91.17% while CVE is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
26.08%
Equity/share CAGR of 26.08% while CVE is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
926.54%
Dividend/share CAGR of 926.54% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
394.15%
Dividend/share CAGR of 394.15% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
16.75%
3Y dividend/share CAGR of 16.75% while CVE is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
11.27%
AR growth well above CVE's 11.80%. Michael Burry fears inflated revenue or higher default risk in the near future.
25.00%
We show growth while CVE is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.33%
Asset growth well under 50% of CVE's 3.07%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
8.72%
BV/share growth above 1.5x CVE's 2.98%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
0.46%
We have some new debt while CVE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-35.43%
We cut SG&A while CVE invests at 59.90%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.